Presentation is loading. Please wait.

Presentation is loading. Please wait.

Current status of development

Similar presentations


Presentation on theme: "Current status of development"— Presentation transcript:

1 Current status of development
Indigenous PCV 15 - An affordable, Asia specific Pneumococcal Conjugate Vaccine – Current status of development M. Kuppusamy, Ph.D Managing Director, Tergene Biotech Pvt. Ltd., Hyderabad

2 Pneumococcal Conjugate Vaccine Design
PCV - 15 Pneumococcal Conjugate Vaccine Design Serotypes included: 15 types of pneumococcal polysaccharides 1, 2, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 23F Source of Strains: CDC, Atlanta Carrier protein: CRM 197 Diphtheria Toxin (Non-recombinant) Conjugation Chemistry: Cyanalation, Adipic acid linker, Carbo-di-imide cross linking

3 Vaccine Formulations PCV - 15 PCV 7 PCV 10 PCV 13 PCV 15 4 6B 9V 14
2 12F

4 Region wise Serotype Coverage
PCV - 15 Region wise Serotype Coverage Region PCV 7 PCV 10 PCV 13 PCV 15 North America 78 % 81 % 88 % 89 % Europe 67 % 76 % Latin America 53 % 72 % 82 % 83 % Oceania 65 % 80 % Africa 40 % 63 % 77 % Asia 48 % 66 % 74 % * Pneumococcal Regional Serotype Distribution for Pneumococcal AMC TPP, 2008

5 Current Status of PCV - 15 PCV - 15
In House technology development & Proof of concept established in 2010 Production of GMP lots for pre-clinical and clinical studies under progress Commercial launch expected in 4th quarter of 2014 Project supported by DBT, Govt. of India

6 PCV - 15 THANK YOU!


Download ppt "Current status of development"

Similar presentations


Ads by Google